Live feed06:00:00·36dPRReleasevia QuantisnowOS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic OsteosarcomaByQuantisnow·Wall Street's wire, on your screen.OSTX· OS Therapies IncorporatedHealth Care
